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Performance characteristics of the venous clinical
severity score
Mark H. Meissner, MD, Cynthia Natiello, RN, BSN, and Stephen C. Nicholls, MD, Seattle, Wash
Objective: To facilitate study of the natural history and management of venous disease, a 10-component venous clinical
severity (VCS) score has been proposed as an objective measure of disease severity. The purpose of this study was to
evaluate the validity and reliability of this instrument.
Methods: VCS component scores (0 to 3) for pain, varicose veins, edema, pigmentation, inflammation, induration,
stocking use, and ulcer size, duration, and number were measured in consecutive patients with chronic venous disease.
Differences between observers (n  3) and on serial evaluation by the same observer were determined.
Results: One hundred twenty-eight limbs in 64 patients were evaluated. Mean VCS score increased from CEAP class 0
(1.7 1.8) to class 6 (14.7 3.0; R .84; P < .0001). Scores in 68 limbs evaluated twice by the same observer differed
by a mean of only 0.8 (P  .15), with a reliability coefficient of 0.6. Mean scores of 8.0 ( 5.1), 7.2 ( 5.1), and 8.0 (
5.4) were obtained in 63 limbs evaluated by all three investigators (P  .02). Only the component scores for pain,
inflammation, and pigmentation showed significant (P < .05) interobserver variability. Interobserver agreement on the
absence of disease or presence of severe disease as defined by scores of 3 or less or 8 or more was good (  0.59 and 0.65,
respectively).
Conclusion: The VCS score is a critically needed tool for evaluating changes in venous disease over time. The score is
reliable and shows good correlation with CEAP clinical classification. (J Vasc Surg 2002;36:889-95.)
The study of any disease is critically dependent on the
ability to objectively document outcome, which may in-
clude clinical, quality of life, and economic measures.1 Such
measures are important not only in defining the natural
history of a chronic disease but also in the design of clinical
trials. For some diseases, such as acute deep venous throm-
bosis, simple measures such as recurrent venous thrombo-
embolism may provide an objective, although incomplete,
measure of outcome. Unfortunately, measuring outcome
in chronic venous disease (CVD) is more complicated
because a number of signs and symptoms may be variably
present in patients with different disease etiologies. Several
means of measuring and classifying the clinical manifesta-
tions of CVD have been proposed.1,2 Although some have
been incorporated into clinical reports3 and randomized
clinical trials,4 few instruments have been validated and
none have been recognized as a standard outcome measure
for CVD.
The ideal clinical outcome measure for CVD would
include the full spectrum of disease and be sufficiently
sensitive to allow stabilization, improvement, or deteriora-
tion to be precisely quantified. In addition, any outcome
measure must be clinically relevant and reproducible. That
is, the instrument’s ability to quantify what it is intended to
measure (validity), to produce consistent results when ad-
ministered on several occasions to stable subjects (reliabil-
ity), and to detect clinically important differences (respon-
siveness) must be shown.5
The clinical component of the CEAP classification6
system has been widely adopted as a descriptive means of
categorizing patients. However, many components of the
CEAP clinical classification are static over time and not
optimally suited to describing subtle changes in a patient’s
clinical condition.7 In an attempt to move beyond report-
ing standards to outcome assessment,8 the American Ve-
nous Forum has developed a 30-point scoring instrument
for quantifying disease severity as part of a comprehensive
system defining the clinical manifestations, associated dis-
ability, and underlying pathophysiologic features of CVD.7
The venous clinical severity (VCS) score includes nine
clinical characteristics graded from 0 to 3 and additional
points to adjust for the background use of compression
stockings (Table I). The VCS score was specifically de-
signed to include only those manifestations of CVD that
can potentially change over time.7 Despite the potential
utility of this instrument, it has not yet been validated. The
goals of this study were threefold: to evaluate the relation-
ship between CEAP clinical classification and VCS score, to
evaluate the reproducibility of VCS scores on serial evalua-
tions by the same observer, and to evaluate interobserver
variability.
METHODS
As a component of their routine clinical assessment,
consecutive patients referred to a general vascular surgery
clinic with manifestations of CVD were evaluated with the
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VCS score. Subjects represented a spectrum of CEAP clin-
ical classification 2 through 6 disease referred for follow-up
of an acute deep venous thrombosis or evaluation of vari-
cose veins, venous edema, skin changes, or ulceration.
Telangiectasias and reticular veins are not considered to be
major pathologic features of CVD, and CEAP classification
1 limbs were excluded from this study. An underlying
venous etiology was confirmed with venous duplex ultra-
sonography in all patients. As VCS scores were determined
as part of routine care, the evaluators were not uniformly
blinded to the ultrasound scan results.
Investigators in this study included a vascular nurse
(observer 1) and two vascular surgeons (observers 2 and 3).
Observers 1 and 3 routinely participate in venous research
protocols, and the experience of observer 2 was primarily
clinical. Although all observers had some knowledge of
venous disease, none had specific training or previous ex-
perience with comparative scoring. CEAP clinical classifi-
cation was determined by the first clinician to evaluate the
subject. Both lower extremities, even if asymptomatic, were
then scored by at least one of the three investigators. All
observers were blinded to the scores determined by the
other investigators. Scores were prospectively entered into
the patient’s medical record on standardized forms that
included a description of the diagnostic features of each of
the 10 VCS components. To evaluate the VCS score exactly
as proposed, none of the components were defined beyond
the descriptions shown in Table I. Abstraction of this
prospectively collected data was approved by the Human
Subjects Committee at the University of Washington.
In evaluation of the relationship between CEAP clinical
classification and VCS score, the mean VCS score of all
observers was used. In definition of thresholds for disease
severity, CEAP classes 2 and 3 were considered to represent
mild to moderate disease and classes 4 through 6 severe
venous disease. Not all limbs were evaluated by all three
observers or more than once by the same observer. Only
limbs scored by all three observers on the same day were
used in the assessment of interobserver variability. Limbs
scored twice by the same observer at least 7 days but not
more than 28 days apart were used in the evaluation of
intraobserver reproducibility. Patients undergoing any in-
tervention other than compression and wound care were
excluded from analysis of intraobserver variability. How-
ever, these patients were included in all other analyses.
All data are reported as the mean ( the standard
deviation). As a measure of validity, the relationship be-
tween VCS score and CEAP clinical classification was de-
Table I. VCS score
Attribute Absent  0 Mild  1 Moderate  2 Severe  3
Pain None Occasional, not
restricting activity or
requiring analgesics
Daily, moderate activity
limitation, occasional
analgesics
Daily, severe limiting activities
or requiring regular use of
analgesics
Varicose veins* None Few, scattered branch
varicose veins
Multiple: GS varicose veins
confined to calf or thigh
Extensive: thigh and calf or GS
and LS distribution
Venous edema† None Evening ankle edema
only
Afternoon edema, above
ankle
Morning edema above ankle and
requiring activity change,
elevation
Skin pigmentation‡ None or focal,
low intensity
(tan)
Diffuse, but limited in
area and old (brown)
Diffuse over most of gaiter
distribution (lower
third) or recent
pigmentation (purple)
Wider distribution (above lower
third) and recent
pigmentation
Inflammation None Mild cellulitis, limited
to marginal area
around ulcer
Moderate cellulitis,
involves most of gaiter
area (lower third)
Severe cellulitis (lower third and
above) or significant venous
eczema
Induration None Focal, circummalleolar
(5 cm)
Medial or lateral, less than
lower third of leg
Entire third of leg or more
No. of active ulcers 0 1 2 2
Active ulceration,
duration§
None 3 mo 3 mos. 1 y Not healed 1 y
Active ulcer, size None 2 cm in diameter 2 to 6 cm in diameter 6 cm in diameter
Compressive therapy Not used or not
compliant
Intermittent use of
stockings
Wears elastic stockings
most days
Full compliance: stockings 
elevation
Qualifying comments:
*“Varicose” veins must be 4 mm in diameter to qualify so that differentiation is ensured between C1 and C2 venous pathology.
†Presumes venous origin by characteristics (eg, brawny [not pitting or spongy] edema), with significant effect of standing/limb elevation or other clinical
evidence of venous etiology (ie varicose veins, history of deep venous thrombosis). Edema must be regular finding (eg, daily occurrence). Occasional or mild
edema does not qualify.
‡Focal pigmentation over varicose veins does not qualify.
§Largest dimension/diameter of largest ulcer.
Sliding scale to adjust for background differences in use of compressive therapy.
GS, Greater saphenous; LS, lesser saphenous.
(Reprinted with permission from Rutherford RB, Padberg FT, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: An adjunct to
venous outcome assessment. J Vasc Surg 2000;31:1307-12.)
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termined with linear regression. The VCS score is primarily
an evaluative rather than a descriptive instrument and is
thus designed to detect differences in individuals over time
rather than describe the spectrum of disease in a popula-
tion. However, the ability to distinguish absent (CEAP 0),
mild to moderate (CEAP 2 to 3), and severe (CEAP 4 to 6)
venous disease has some utility in classifying changes in
individual patients. The VCS decision thresholds for distin-
guishing these three disease categories were therefore se-
lected using receiver operating characteristic analysis with
Rockit statistical software (C. E. Metz, Department of
Radiology, University of Chicago).9,10
Differences between VCS scores determined by the
same observer on different days were evaluated with the
paired t test. The reliability coefficient, which reflects the
proportion of total variance due to true differences among
subjects, was calculated from the paired measurements as
the ratio of subject variance to total variance (between-
subject variance/[between-subject variance  within-sub-
ject variance]). A change in score should be used as an
outcome measure only when the reliability coefficient ex-
ceeds 0.5.11 Differences in overall and component VCS
scores between observers were compared with repeated
measures analysis of variance using orthonormalized differ-
ence contrasts.12 This analysis compares each observer’s
score with the average of the previous observers’ scores.
Agreement in categorizing the absence of venous disease or
the presence of severe venous disease was evaluated using
two-by-two tables (paired observers) or an intraclassifica-
tion correlation coefficient (three observers) to calculate a 
statistic.13  varies between a value of 1 for perfect agree-
ment and 0 for no agreement beyond that due to chance. 
values of more than 0.75 usually represent excellent agree-
ment beyond chance, values between 0.40 and 0.75 fair to
good agreement, and values less than 0.4 poor agree-
ment.13 Statistical significance for all comparisons was de-
fined at a P value of .05 or less.
RESULTS
Between May and November 2000, one hundred
twenty-eight limbs in 64 consecutive patients were pro-
spectively scored by at least one investigator. Subjects in-
cluded 37 males (58%) and 27 females (42%) and had a
mean age of 53.1 years ( 15.1 years). Limbs included 25
CEAP clinical class 0 (asymptomatic), 40 class 2 (varicosi-
ties), six class 3 (edema), 13 class 4 (skin changes), 17 class
5 (healed ulcer), and 27 class 6 (active ulcer) extremities.
The mean VCS score among these limbs was 7.2 ( 5.0)
and progressively worsened from 1.7 ( 1.8) in CEAP class
0 limbs to 14.7 ( 3.0) in class 6 extremities (Fig 1). Mean
VCS score was highly correlated with CEAP clinical class
(R  0.84; P  .001).
Definition of venous disease as absent, mild to moder-
ate, or severe requires differentiating absent from any ve-
nous disease (CEAP 0 versus CEAP 2 to 6) and absent to
moderate from severe disease (CEAP 0 to 3 versus CEAP 4
to 6). The mean VCS score and 95% CIs for these catego-
ries were 1.7 (1.0 to 2.4) for absent disease, 3.9 (3.3 to 4.5)
for absent to moderate disease, and 11.2 (10.0 to 12.3) for
severe disease. The receiver operating characteristic curves
Fig 1. Boxplot of VCS scores within CEAP clinical classifications. Top, middle, and bottom lines of box represent 75th,
50th (median), and 25th percentiles. Closed square shows mean, with top and bottom whiskers representing 90th and
10th percentiles. Correlation of VCS score with CEAP clinical classification is statistically significant (R  0.84; P 
.001). 95% CI for mean VCS scores are 1.0 to 2.4 (classification 1), 4.5 to 5.8 (classification 2), 3.2 to 6.3 (classification
3), 6.6 to 8.9 (classification 4), 6.8 to 9.7 (classification 5), and 13.6 to 15.8 (classification 6).
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for distinguishing absent from any venous disease and
absent to moderate from severe disease are shown in Fig 2.
Erring on the side of a strict threshold (higher specificity),
a VCS score of 3 or less was associated with a sensitivity and
specificity of 76% and 90%, respectively, for the absence of
disease, and a threshold of 8 or more had a sensitivity and
specificity of 70% and 96%, respectively, for the presence of
severe disease.  values for agreement between these VCS
thresholds and disease severity as defined by CEAP criteria
were 0.63 for the absence of disease and 0.68 for the
presence of severe disease. Lax VCS thresholds of 4 or less
and 7 or more would increase sensitivity at the expense of
specificity.
Sixty-eight extremities were scored twice within a 28-
day period by the same investigator. The mean interval
between evaluations was 17.2 days ( 8.6 days). Mean
VCS scores on the first (11.1  6.0) and second (11.9 
5.2) evaluations were not significantly different (P  .15).
Between-subject variance (27.2) exceeded within subject
variance (17.7), giving a reliability coefficient of 0.6.
Sixty-three limbs were evaluated by all three observers
on the same day. Differences in mean VCS scores between
the three observers were small although statistically signif-
icant (P  .02). The scores of observer 1 and observer 2
differed by a mean of only 0.8 (P  .03), and those of
observer 3 differed from the others by a mean of only 0.4
(P .11). Overall and component VCS scores are shown in
Table II. Scores for pain, skin pigmentation, and inflamma-
tion differed slightly but significantly between the three
observers, and those for varicose veins, edema, induration,
compression therapy, and ulcer number, duration, and size
were not significantly different. Pairwise  values for defin-
ing the absence of venous disease (class 0) and the presence
of severe disease (class 4 to 6) on the basis of VCS scores of
3 or less and 8 or more, respectively, are shown in Table III.
Agreement between all three observers was relatively good,
with overall  values of 0.59 for the absence of disease and
0.65 for the presence of severe disease.
DISCUSSION
An evidence-based approach to the treatment of any
disease requires a mechanism for ensuring that patient
Fig 2. Receiver operating characteristic curves for detection of absent disease versus disease (CEAP 0 versus CEAP 2
to 6, dashed line) and absent to moderate versus severe disease (CEAP 0 to 3 versus CEAP 4 to 6, solid line). Various
thresholds for detection of absent (closed circles) and severe (open circles) disease are illustrated on curves. Area under
absent disease curve  0.94; area under severe disease curve  0.93.
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populations are comparable and a means of quantifying
outcome. However, the goals of describing differences
between individuals (discriminative instruments) may be
different than detecting longitudinal changes within indi-
viduals (evaluative instruments), and different measure-
ments may be necessary for these two purposes.5,11,14
Discriminative instruments require large and stable be-
tween-subject variation, while evaluative instruments
should have small within-subject variances in stable patients
and allow significant changes in response to improvement
or deterioration.14 The CEAP clinical classification as pro-
posed in the updated reporting standards for venous dis-
ease6 has proven useful in categorizing patients and should
continue to be used as a discriminative instrument. The
CEAP classification has good intraobserver reproducibility
(  0.85), although interobserver reproducibility is
poorer (  0.47).15 However, the broad classifications
included in CEAP are less responsive for quantifying out-
come and have prompted development of the VCS scoring
system.
The ideal instrument for quantifying venous disease
severity would be objective, applicable to the entire spec-
trum of CVD, have both clinical and biologic relevance,
and be sensitive to changes in clinical status. The last feature
requires inclusion of critical, dynamic features of the dis-
ease, which can be quantified not only in terms of progres-
sion, an important aspect of the natural history of the
disease, but also improvement in response to an interven-
tion. In addition, any measurement instrument must be
valid, reliable, and responsive to change. Validity reflects
whether an instrument is measuring what it intends to
measure, usually by comparison with a gold standard.16
The use of score changes to define outcome further de-
pends on the reliability of a measurement, that is, the
degree to which an instrument yields stable results in re-
peated trials.5,11 Reliable evaluative instruments should
have small within-subject variance in stable patients14 as
reflected by a reliability coefficient greater than 0.5.11 Fi-
nally, responsiveness depends on defining the change in
subject score that constitutes a clinically important differ-
ence and is calculated as the ratio of clinically important
difference to the variability in stable subjects.5
The results of this study suggest that the VCS score is
valid, scores increasing in a linear fashion with CEAP
clinical disease class. This is not surprising because the VCS
score was specifically designed to preserve the CEAP hier-
archy of disease severity.7 Selection of threshold VCS scores
on the basis of high specificity allows definition of absent
(3), mild to moderate (4 to 7), and severe (8) disease
categories that show good agreement with the CEAP clas-
sification. The good but imperfect separation of disease
classifications does not detract from the utility of the instru-
ment. A descriptive instrument such as CEAP should excel
at classifying groups of patients into precise disease catego-
ries, while the capacity of an evaluative instrument, such as
the VCS score, to detect true changes within a patient is far
more relevant than its ability to distinguish between disease
classifications.
Most importantly, the VCS instrument is reliable11,16
in tests of intraobserver variability. Limbs scored twice by
the same observer within a 28-day period were not signifi-
cantly different, and the reliability coefficient is sufficiently
high to use a change in scores as an outcome measure.
Although small but significant differences were present
between observers, interobserver reproducibility was also
relatively good. Overall VCS scores of the three observers
differed by only 0.4 to 0.8. Agreement between observers
in assigning patients to one of the three disease categories
(absent, mild to moderate, and severe) was also reasonable
and similar to the intraobserver variability in interpreting
lung scintigraphy ( 0.54),17 lower extremity venograms
(  0.57 to 0.67),18 and angiographic classification of
carotid stenosis (  0.68).19
The small differences between observers do, however,
suggest some limitations in the proposed scoring system.
Table II. Component VCS scores (mean  standard deviation)
Component Observer 1 Observer 2 Observer 3 P
Pain 1.2 ( 1.1) .8 ( 0.9) 1.0 ( 0.9) .001
Varicose veins 1.3 ( 1.1) 1.0 ( 1.1) 1.3 ( 1.1) .06
Venous edema 1.4 ( 1.2) 1.1 ( 1.1) 1.2 ( 1.1) .07
Skin pigmentation 1.0 ( 1.0) 0.7 ( 0.8) 0.9 ( 1.0) .02
Inflammation 0.1 ( 0.4) 0.3 ( 0.6) 0.3 ( 0.7) .02
Induration 0.6 ( 0.9) 0.5 ( 0.9) 0.7 ( 1.2) .2
Active ulcer, number 0.3 ( 0.5) 0.3 ( 0.5) 0.3 ( 0.5) .9
Active ulcer, duration 0.4 ( 0.9) 0.5 ( 1.0) 0.4 ( 0.9) .1
Active ulcer, size 0.4 ( 0.8) 0.5 ( 0.9) 0.4 ( 0.9) .1
Compression therapy 1.4 ( 1.4) 1.4 ( 1.4) 1.4 ( 1.4) .4
Overall VCS score 8.0 ( 5.1) 7.2 ( 5.1) 8.0 ( 5.4) .02
Table III. Interobserver agreement in severity of disease
Classification Observers Agreed Disagreed 
Absent 1 versus 2 54 9 0.56
Disease 1 versus 3 58 5 0.71
(VCS  3) 2 versus 3 53 10 0.52
Severe 1 versus 2 48 15 0.52
Disease 1 versus 3 54 9 0.71
(VCS  8) 2 versus 3 55 8 0.73
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High reliability has previously been shown in rating vari-
cose vein severity, ankle edema, and ankle flare.1 Scores for
ulcer characteristics and the use of compression were also
highly reproducible in this study. However, there were
significant differences is the component scores for pain, skin
pigmentation, and inflammation that may warrant minor
modifications. Pain is perhaps the most subjective, nonspe-
cific component of the VCS score, and poor intraobserver
reproducibility has been noted by others.15 However, the
moderate and severe pain categories are not mutually ex-
clusive and could perhaps be revised. Simply clarifying that
the highest level of activity restriction or analgesic use
should be used in scoring pain might minimize this overlap.
Furthermore, analgesic use is poorly defined, and perhaps
the definition should be clarified to specifically include
prescription antiinflammatory and narcotic agents. With
respect to skin pigmentation, recent pigmentation could
perhaps be eliminated from category 2 and made the pri-
mary diagnostic element in category 3. Finally, use of the
term cellulitis in scoring inflammation may be confusing,
potentially implying infection rather than erythema from
venous flare. Changing the term cellulitis to erythema and
noting that this is not the result of invasive infection could
eliminate this source of confusion.
Several other classification systems have been used in
clinical research,3,4,20,21 but few have been formally vali-
dated.1 An 18-point scale was proposed as a component of
the original CEAP document, but scoring was subjective
and the scale has never been validated or widely used.2 The
Venous Insufficiency Epidemiologic and Economic Studies
(VEINES) task force has proposed an ascending score on
the basis of the probability of ulceration. Although the
score may have some predictive value, it was not designed
to detect change or treatment efficacy.1 Villalta and col-
leagues22 have reported a clinical scale for the postthrom-
botic syndrome, variants of which have been used in a
number of natural history studies and clinical trials.4,21,23
This instrument assigns subjective scores of 0 (absent) to 3
(severe) for symptoms of pain, cramps, pruritis, and paras-
thesia and the signs of pretibial edema, induration, hyper-
pigmentation, new venous ectasia, and redness. As reported
in abstract form,22 the  value for agreement between
observers was 0.78 and for differentiation of moderate
versus severe disease 0.75. Potential limitations of this
instrument include subjective rather than precise descrip-
tive scoring of each clinical feature and its restricted appli-
cation to the postthrombotic syndrome.
Although this study supports the validity and reliability
of the VCS instrument, it does have some limitations that
must be recognized. To minimize significant clinical
changes, serial evaluations were performed at least 7 days
but not more than 28 days apart. However, it is possible
that some actual clinical changes may have occurred be-
tween evaluations in patients with more advanced disease.
Previous clinical experience with a patient could also have
influenced serial scoring, although attempts were made to
minimize any bias through use of a standardized form
including detailed descriptions of the objective scoring
criteria. It is also important to note that this study was
performed as part of routine clinical practice by observers
without previous VCS scoring experience. We found the
objective descriptions to be relatively easy to learn and
apply and believe our results are generalizable to most
investigators early in their experience. Notably, the results
of observers 1 and 3, who routinely participate in venous
research, were more concordant than were those of ob-
server 2. This may imply that the results obtained by
dedicated investigators, particularly after appropriate train-
ing in comparative scoring, would be even better. In addi-
tion, although this study included patients with a spectrum
of disease severity, the maximal score measured in any limb
was only 22. Inclusion of limbs with higher scores would be
unlikely to effect validity, although reproducibility could be
affected. Finally, this study did not formally evaluate the
instrument’s responsiveness, a critical feature in calculating
sample sizes for clinical trials.5 However, the score appro-
priately decreases as ulcers heal and limbs move from clas-
sification 5 to classification 6, meeting the limited criteria of
being able to change as CVD progresses or improves.
In conclusion, the VCS score is a critically needed tool
for evaluating outcomes in CVD. It provides an objective
measure of disease severity that serves an adjunct to the
quality of life instruments20,24 that have been developed to
quantify outcome in response to the therapeutic interven-
tion. Furthermore, the VCS score provides an objective
means of quantifying the natural history of CVD, an appli-
cation to which quality of life measures have more limited
utility. The correlation with CEAP classification and lack of
significant intraobserver variability suggests that the instru-
ment provides a valid and reproducible measure of disease
severity. Perhaps not surprisingly, the VCS score is a good,
but imperfect, descriptive instrument as exemplified by the
 values for agreement with CEAP classification. Although
reporting of mean VCS scores for patient groups is appro-
priate, the CEAP clinical classification system should be
retained as a descriptive instrument. Furthermore, the in-
strument could perhaps benefit from minor clarifications in
the descriptions for pain, pigmentation, and inflammation.
Although less critical in a single observer’s evaluation, such
modifications might improve comparisons by different ob-
servers and of different patient groups. Finally, validation of
an instrument does not end with a single study but requires
continued evaluation with repeated use.16 Further evalua-
tion of the instrument, particularly after a period of training
in the research setting, and correlation with quality of life
instruments and the simultaneously proposed venous seg-
mental disease score are still needed.
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